UNC Department of Urology | Strategic Alliance Partners

"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.

"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.

"Teixobactin, and more broadly, the iChip approach to novel antibiotic discovery, is an exciting development in infection control," write Philip Abbosh, MD, PhD, and Kate Gessner, MD, PhD.

"There are many opportunities to support our patients with bladder cancer who smoke from their clinic appointments from their intravesical therapy visits to their surveillance cystoscopies," says Marc Bjurlin, DO, MSc, FACOS.

"Our next goal is transitioning to really understand the patient experience and how we can support them to quit smoking cigarettes," says Marc Bjurlin, DO, MSc, FACOS.

“At the Advocacy Summit earlier this spring, 2 of the 3 leave-behind documents that outlined specific issues related to urology priorities were directly informed by information from the Census,” says Matthew Nielsen, MD, MS, FACS.

Angela B. Smith, MD, MS, highlights key takeaways from the session, “Time Efficiency and Productivity Hacks for the Busy Urologist,” which was presented at the 2024 AUA Annual Meeting.

“We can all learn and collaborate from each other, that way we can continue to provide really great care for our patients,” says Mary W. Dunn, MSN, NP-C, OCN, RN.

"This study identifies a new target for VTE prevention," writes Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.

"This work and previous work supports the idea that EBV not only causes MS, but also continues to affect disease progression," write the authors.

"Understanding work productivity and activity impairment in the context of the treatment decisions are vital, not just for the provider who has to counsel on treatment benefits and risks, but also to the patient who's making the ultimate decision," says Angela Smith, MD, MS.

"From a urology provider perspective, we should be discussing this with our patients [with bladder cancer] as they make their treatment decisions," says Angela Smith, MD, MS.

"When we put this course together, we didn't want it to be a course about working more; it was really about working more efficiently, so that you can gain more time outside of work," says Angela B. Smith, MD, MS.